NANOLOGICA AB - December 20, 2021
- Press releases, Regulatory press releases
Theoption program 2021/24 for Nanologica AB resolved by the Annual General Meeting 2021 has now been implemented. The program was subscribed at 100 percent by both the management team, including the CEO, and employees.
At the Annual General Meeting on May 27, 2021, a new stock option program was resolved, which has now been implemented. In option program 2021/24 for Nanologica's management and employees, 800,000 of the total 800,000 options have been subscribed for.
" The fact that the program was fully subscribed by both the management team and employees indicates a continued strong belief internally in the company and that we will deliver on our goals. We continue our work to develop Nanologica into a profitable company with full force and look forward to an eventful 2022″, comments CEO Andreas Bhagwani.
The terms for the stock option program stipulate that each option entitles the holder to subscribe for one (1) share in the company at a subscription price corresponding to SEK 45. Based on the current number of shares in the company, the maximum dilution will be approximately 2.8 percent if all options are subscribed for. The period for exercising the stock options is April 1, 2024 to July 1, 2024.
For further information, please contact:
Johanna Johansson, IR Manager
Ph: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases. In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje and the company's share (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Nanologica AB published this content on 20 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 December 2021 07:19:05 UTC.
